Clinical Trials Logo

Clinical Trial Summary

Dementia is one of the main chronic non-communicable diseases associated with disability, institutionalization, and mortality among elderly individuals. Alzheimer's disease (AD) and vascular dementia (VD) are considered to be the main types of dementia. A widely shared view is that future treatment strategies need to focus on treatment of the earliest stages of the disease. Mild cognitive impairment (MCI) constitutes an intermediate stage between normal aging and dementia. Vascular cognitive disorders (VCD) is an umbrella term representing a wide spectrum of cognitive disorder evoked by or associated with vascular causes. It encompasses patients suffering from a range of types of cognitive impairment, from mild impairment to VD. VCD predementia (VCD-P) is at the same stage of MCI. Amnestic MCI (aMCI) is a subtype of MCI, which is also considered to be the clinical transition stage between normal aging and AD, and has been applied to detect the emerging dementia. In VCD, infarcts or profuse white matter disease are considered the cause of cognitive decline. By contrast, AD is one of the most common progressive neurodegenerative disorders thought to be caused by amyloid aggregation and the formation of tau tangles. Both VCD-P and aMCI have a deficit in cognitive domains, and may have the same chief complaints of memory deficit. If it can be clear which will turn into what type of dementia in patients with cognitive impairment stage, it can not only make us more early intervention treatment to the patients, but also can save a lot of social resources and economic costs in clinic. By applying the resting state functional magnetic resonance (fMRI), structural magnetic resonance imaging (sMRI) and diffusion tensor magnetic resonance imaging (DTI) multimodal magnetic resonance (NMR) technology, the project comprehensive analysis comparison of neurodegenerative and blood vessels of brain function in patients with mild cognitive impairment and structural abnormalities connection mode. This project in order to reveal the cognitive impairment disease neural circuits in the development of the network connection and its change rule. People can further understand the pathogenesis of cognitive impairment, discover new will provide a scientific basis for prevention, diagnosis and treatment.


Clinical Trial Description

The investigators use both psychological tests and neuroimage to compare the differences between the two groups.

All the participants received a battery of neuropsychological tests to assess general mental status and other cognitive domains, including visual-spatial ability, executive function, language, memory, attention, and general intellectual ability. These tests included the CDR scale, the Mini-Mental State Examination(MMSE), the Montreal Cognitive Assessment(MoCA), clock drawing test (CDT), Auditory Verbal Learning Test (AVLT), activities of daily living scale(ADL) and Hamilton Depression Scale and HIS. All these evaluations were performed by two attending neurologists.

All participants were scanned on a 3.0 T Siemens scanner within a single session.

Each participant received a magnetization prepared rapidly acquired gradient echo (MPRAGE) T1-weighted scan (repetition time [TR], 1900 ms; echo time [TE], 2.2 ms; inversion time, 900 ms; matrix, 256×256; number of excitations, 1; thickness, 1 mm; 176 slices) Resting state functional images were collected using an echo-planar imaging (EPI) sequence with the following parameters: repetition time (TR)= 2000 ms; echo time (TE)=40 ms; flip angle=90°; number of slices=28; slice thickness=4 mm; gap=1 mm; voxel size=4×4×4 mm3; and matrix=64×64. Participants were asked to lie quietly in the scanner with their eyes closed during the data acquisition. This scan lasted for 478 s. For each subject, the first five volumes were discarded to allow for T1 equilibration effects and the adaptation of the subjects to the circumstances, leaving 234 images for further analysis.

The diffusion weighted imaging scans were acquired on a 3.0T Siemens Tim Trio MRI scanner. Three diffusion echo-planar imaging sequence with one zero-weighted image (b =0 s/mm2) and thirty diffusion sensitizing orientations (b =1000 s/mm2) was used with the following specifications: slice thickness=2 mm; 90 slices; repetition time = 11000 ms; echo time = 98 ms; voxel size = 2 mm isotropic; flip angle=90°; acquisition matrix = 128 mm×116 mm . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02706210
Study type Observational
Source Mudanjiang Medical University
Contact Changhao Yin
Phone 86 13845307558
Email yinchanghao7916@sina.com
Status Recruiting
Phase N/A
Start date September 2015
Completion date December 2018

See also
  Status Clinical Trial Phase
Completed NCT04513106 - Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial N/A
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Active, not recruiting NCT03167840 - Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment N/A
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Not yet recruiting NCT05041790 - A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment Phase 4
Recruiting NCT04121156 - High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT02774083 - Cognitive Training Using Feuerstein Instrumental Enrichment N/A
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Enrolling by invitation NCT06023446 - Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT05579236 - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT03583879 - Using Gait Robotics to Improve Symptoms of Parkinson's Disease N/A
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Active, not recruiting NCT05204940 - Longitudinal Observational Biomarker Study
Recruiting NCT02663531 - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease N/A
Recruiting NCT06150352 - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Recruiting NCT03507192 - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia. N/A